These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35038723)

  • 21. Randomized trial of intravenous immunoglobulin maintenance treatment regimens in chronic inflammatory demyelinating polyradiculoneuropathy.
    Kuitwaard K; Brusse E; Jacobs BC; Vrancken AFJE; Eftimov F; Notermans NC; van der Kooi AJ; Fokkink WR; Nieboer D; Lingsma HF; Merkies ISJ; van Doorn PA
    Eur J Neurol; 2021 Jan; 28(1):286-296. PubMed ID: 32876962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An international multicenter efficacy and safety study of IqYmune in initial and maintenance treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy: PRISM study.
    Nobile-Orazio E; Pujol S; Kasiborski F; Ouaja R; Corte GD; Bonek R; Cocito D; Schenone A
    J Peripher Nerv Syst; 2020 Dec; 25(4):356-365. PubMed ID: 32808406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protocol of a dose response trial of IV immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (DRIP study).
    Kuitwaard K; Fokkink WR; Brusse E; Vrancken AFJE; Eftimov F; Notermans NC; van der Kooi AJ; Merkies ISJ; Jacobs BC; van Doorn PA
    J Peripher Nerv Syst; 2018 Mar; 23(1):5-10. PubMed ID: 29119642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.
    Hughes RA; Gorson KC; Cros D; Griffin J; Pollard J; Vallat JM; Maurer SL; Riester K; Davar G; Dawson K; Sandrock A;
    Neurology; 2010 Feb; 74(8):651-7. PubMed ID: 20177118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study.
    Hahn AF; Bolton CF; Zochodne D; Feasby TE
    Brain; 1996 Aug; 119 ( Pt 4)():1067-77. PubMed ID: 8813271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.
    Merkies ISJ; van Schaik IN; Léger JM; Bril V; van Geloven N; Hartung HP; Lewis RA; Sobue G; Lawo JP; Durn BL; Cornblath DR; De Bleecker JL; Sommer C; Robberecht W; Saarela M; Kamienowski J; Stelmasiak Z; Tackenberg B; Mielke O;
    J Peripher Nerv Syst; 2019 Mar; 24(1):48-55. PubMed ID: 30672091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin.
    Vu T; Anthony N; Alsina R; Harvey B; Schleutker A; Farias J; Dang S; Suresh N; Gooch C
    Muscle Nerve; 2021 Sep; 64(3):351-357. PubMed ID: 34076265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.
    Oaklander AL; Lunn MP; Hughes RA; van Schaik IN; Frost C; Chalk CH
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010369. PubMed ID: 28084646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy.
    Seino Y; Nakamura T; Hirohata M; Kawarabayashi T; Okushima T; Shoji M
    Intern Med; 2019 Mar; 58(6):855-859. PubMed ID: 30449785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune Globulin Subcutaneous (Human) 20% (Hizentra
    Lamb YN; Syed YY; Dhillon S
    CNS Drugs; 2019 Aug; 33(8):831-838. PubMed ID: 31347096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of relapse by inflammatory Rasch-built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy.
    Merkies ISJ; van Schaik IN; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR;
    J Peripher Nerv Syst; 2022 Jun; 27(2):159-165. PubMed ID: 35266243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous immunoglobulin therapy for small fiber neuropathy: study protocol for a randomized controlled trial.
    de Greef BT; Geerts M; Hoeijmakers JG; Faber CG; Merkies IS
    Trials; 2016 Jul; 17(1):330. PubMed ID: 27439408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study.
    RMC Trial Group
    Lancet Neurol; 2009 Feb; 8(2):158-64. PubMed ID: 19136303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy.
    Donofrio PD; Bril V; Dalakas MC; Deng C; Hanna K; Hartung HP; Hughes R; Latov N; Merkies I; van Doorn P;
    Arch Neurol; 2010 Sep; 67(9):1082-8. PubMed ID: 20837852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy.
    Kuitwaard K; van den Berg LH; Vermeulen M; Brusse E; Cats EA; van der Kooi AJ; Notermans NC; van der Pol WL; van Schaik IN; van Nes SI; Hop WC; van Doorn PA
    J Neurol Neurosurg Psychiatry; 2010 Dec; 81(12):1374-9. PubMed ID: 20587484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy.
    Hughes R; Bensa S; Willison H; Van den Bergh P; Comi G; Illa I; Nobile-Orazio E; van Doorn P; Dalakas M; Bojar M; Swan A;
    Ann Neurol; 2001 Aug; 50(2):195-201. PubMed ID: 11506402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment timing and choice of outcome measure in determining treatment response in chronic inflammatory demyelinating polyneuropathy: A post hoc analysis of the PRISM trial.
    Rajabally YA; Ouaja R; Kasiborski F; Pujol S; Nobile-Orazio E
    Muscle Nerve; 2022 Nov; 66(5):562-567. PubMed ID: 36057106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta-analysis.
    Racosta JM; Sposato LA; Kimpinski K
    Muscle Nerve; 2017 Jun; 55(6):802-809. PubMed ID: 27649063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longer-term effects of intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: Who benefits?
    Terhoeven P; Seybold J; Utz KS; Nickel FT; Lee DH; Linker RA
    J Neurol Sci; 2020 Dec; 419():117169. PubMed ID: 33035867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic Inflammatory Demyelinating Polyneuropathy: Time to Maximal Recovery in Patients Receiving Intravenous Immunoglobulin Therapy.
    Opala AR; Kennedy K; Baker SK
    Can J Neurol Sci; 2020 Jul; 47(4):531-537. PubMed ID: 32279669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.